(R)-N-(1-phenylethyl)but-3-en-1-amine | 177944-16-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (R)-N-(1-phenylethyl)but-3-en-1-amine
• 英文别名: N-[(1R)-1-phenylethyl]but-3-en-1-amine
• CAS: 177944-16-0
• 化学式: C₁₂H₁₇N
• 分子量: 175.274
• InChiKey: BXQDWPXPKVWDGU-LLVKDONJSA-N

物化性质

• 沸点：
  243.6±19.0 °C(Predicted)
• 密度：
  0.908±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (R)-N-(1-phenylethyl)but-3-en-1-amine 在 氨 作用下， 以 乙腈 为溶剂， 反应 4.0h， 生成 methyl (2R,4S)-4-hydroxy-1-((R)-1-phenylethyl)piperidine-2-carboxylate
  参考文献：
  名称：

  Asymmetric synthesis of cis-(−)-(2R4S)-4-(phosphonomethyl)-2-piperidinecarboxylic acid, a potent NMDA receptor antagonist

  摘要：

  The asymmetric synthesis of cis-(-)-(2R4S)-4-(phosphononomethyl)-2-piperidinecarboxylic acid (1), a potent and specific NMDA receptor antagonist, via an olefin-iminium cyclization is described. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0960-894x(96)00150-3
• 作为产物：
  描述：

  丁-3-烯-1-醇,4-甲基苯磺酸 、 R(+)-alpha-甲基苄胺 在 三乙胺 作用下， 生成 (R)-N-(1-phenylethyl)but-3-en-1-amine
  参考文献：
  名称：

  Novel constrained CCK-B dipeptoid antagonists derived from pipecolic acid

  摘要：

  A new series of 4-substituted pipecolic acid derivatives was prepared and incorporated into dipeptoids. The resulting products behave as moderately potent CCK-B antagonists but their constrained structure and its comparison with structurally related compounds yield valuable information about the conformational requirements for optimal recognition of the CCK-B receptor by antagonists. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00231-5

文献信息

• (Indazol-4-YL) Hexahydropyrrolopyrrolones and Methods of Use
  申请人：AbbVie Inc.

  公开号：US20160264582A1

  公开（公告）日：2016-09-15

  Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein G Ar , L 1 , Z 1 and Z 2 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Na v 1.7 and/or Na v 1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

  式（I）的化合物及其药用可接受的盐、酯、酰胺或放射标记形式，其中G、Ar、L1、Z1和Z2如规范中所定义，可用于治疗由电压门控钠通道如Na v 1.7和/或Na v 1.8预防或改善的病症或紊乱。公开了制备这些化合物的方法。还公开了式（I）化合物的药物组合物，以及使用这些化合物和组合物的方法。
• Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof
  申请人：Lampe Thomas

  公开号：US20110124665A1

  公开（公告）日：2011-05-26

  The present application relates to novel, cyclically substituted furopyrimidine derivatives, methods for their production, their use for the treatment and/or prophylaxis of diseases and their use for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular diseases.

  本申请涉及新型的、环状取代的呋喃嘧啶衍生物，其生产方法，以及它们用于治疗和/或预防疾病的应用，特别用于治疗和/或预防心血管疾病的治疗和/或预防药物的生产。
• Amino−Zinc−Enolate Carbometalation Reactions:  Application to Ring Closure of Terminally Substituted Olefin for the Asymmetric Synthesis of <i>cis</i>- and <i>trans</i>-3-Prolinoleucine
  作者：Philippe Karoyan、Jean Quancard、Jacqueline Vaissermann、Gérard Chassaing

  DOI：10.1021/jo026535n

  日期：2003.3.1

  The reaction is stereospecific, leading to a trans-3-substituted proline derivative, whereas a cis stereochemistry was observed with the amino-zinc-enolate cyclization of terminally nonsubstituted olefins. Absolute configurations obtained for the 3-prolinoleucine were established by X-ray analysis, NMR, and optical activity comparison of the cis and trans derivatives obtained by an unambiguous pathway

  氨基锌烯醇盐环化反应是3-取代脯氨酸合成的直接途径。作为经典的分子内碳金属化反应，将锌加成至双键的适用性限于其中末端烯烃碳未被取代的底物。对合成顺式和反式3-脯氨酰亮氨酸衍生物感兴趣，以进行结构-活性关系（SAR）研究，我们集中精力通过末端取代的双键的氨基-锌-烯酸酯环化制备这些化合物。本文中我们报道活化基团例如环丙基与末端烯烃碳的连接使得末端取代的烯烃的氨基-锌-烯醇酸酯环化。反应是立体特异性的，导致反式3取代的脯氨酸衍生物，而在末端未取代的烯烃的氨基-锌-烯醇酸酯环化中观察到顺式立体化学。通过X射线分析，NMR和通过明确途径获得的顺式和反式衍生物的光学活性比较，确定了3-脯氨酰亮氨酸的绝对构型。
• A 5 + 1 Protic Acid Assisted Aza-Pummerer Approach for Synthesis of 4-Chloropiperidines from Homoallylic Amines
  作者：Rene Ebule、Sagar Mudshinge、Michael H. Nantz、Mark S. Mashuta、Gerald B. Hammond、Bo Xu

  DOI：10.1021/acs.joc.8b03162

  日期：2019.3.15

  We report that HCl·DMPU induces the formation of (thiomethyl)methyl carbenium ion from DMSO under mild conditions. Homoallylic amines react with this electrophile to generate 4-chloropiperidines in good yields. The method applies to both aromatic and aliphatic amines. The use of HCl·DMPU as both non-nucleophilic base and chloride source constitutes an environmentally benign alternative for piperidine

  我们报告说，在温和的条件下，HCl·DMPU可以诱导DMSO生成（硫代甲基）甲基碳正离子。均烯丙基胺与该亲电试剂反应生成4-氯哌啶，收率良好。该方法适用于芳族和脂族胺。使用HCl·DMPU作为非亲核碱和氯化物来源，是哌啶形成的一种环境友好的替代方法。该反应具有广泛的底物范围，并且该条件提供了具有高官能团耐受性和可扩展性的良好化学产率。
• [EN] 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE 3-(5-MÉTHOXY-1-OXOISOINDOLIN-2-YL)PIPÉRIDINE-2,6-DIONE ET LEURS UTILISATIONS
  申请人：NOVARTIS AG

  公开号：WO2021124172A1

  公开（公告）日：2021-06-24

  The present disclosure relates to compounds of formula (I') and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.

  本公开涉及式(I')的化合物、药物组合物及其在降低广泛间隔锌指蛋白结构域（WIZ）表达水平、诱导胎儿血红蛋白（HbF）表达以及治疗遗传性血液疾病（例如，血红蛋白病，例如，β-血红蛋白病）方面的用途，如镰状细胞病和β-地中海贫血。